Matchpoint Therapeutics announced a USD 150 million Series B on Wednesday 7 October 2026, co-led by Nextech Invest and Norwest. The US biotechnology company develops oral small-molecule treatments for autoimmune and inflammatory diseases. The financing supports its pipeline and planned clinical development of its lead candidate. Matchpoint's work focuses on drug design and the research needed to move potential treatments toward studies in people. The announcement is a development-stage investment story, linking specialist life-sciences investors with a company pursuing a defined therapeutic approach. The funding provides capital for the next stages of the programme described by the company and investors.
Matchpoint Therapeutics raises USD 150m Series B
Nextech Invest and Norwest back oral treatments for autoimmune disease

Keep reading
More Funding

BrightAI secures USD 97 million to scale physical AI infrastructure
Smith Point Capital led the investment in sensor based monitoring for essential services.

Dcubed raises EUR 27.2 million to expand space hardware production
Warsaw Equity Group led the oversubscribed Series A plus round for the German manufacturer.

Linq raises USD 90 million to expand AI powered mobile infrastructure
Andreessen Horowitz led the Series B and partner Ben Horowitz joined the board.


